These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 17913444)
1. Potentially useful biomarkers for the diagnosis, treatment and prognosis of lung cancer. Cho WC Biomed Pharmacother; 2007 Oct; 61(9):515-9. PubMed ID: 17913444 [TBL] [Abstract][Full Text] [Related]
2. Biomarkers for lung cancer: clinical uses. Greenberg AK; Lee MS Curr Opin Pulm Med; 2007 Jul; 13(4):249-55. PubMed ID: 17534168 [TBL] [Abstract][Full Text] [Related]
3. Proteomic approaches in lung cancer biomarker development. Cho JY; Sung HJ Expert Rev Proteomics; 2009 Feb; 6(1):27-42. PubMed ID: 19210125 [TBL] [Abstract][Full Text] [Related]
4. Biomarker discovery in lung cancer--promises and challenges of clinical proteomics. Bharti A; Ma PC; Salgia R Mass Spectrom Rev; 2007; 26(3):451-66. PubMed ID: 17407130 [TBL] [Abstract][Full Text] [Related]
6. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer. Holdenrieder S; von Pawel J; Dankelmann E; Duell T; Faderl B; Markus A; Siakavara M; Wagner H; Feldmann K; Hoffmann H; Raith H; Nagel D; Stieber P Clin Cancer Res; 2008 Dec; 14(23):7813-21. PubMed ID: 19047109 [TBL] [Abstract][Full Text] [Related]
7. Clinical utility of tissue polypeptide antigen determination in lung cancer management. Rapellino M; Pecchio F; Baldi S; Scappaticci E; Cavallo A Anticancer Res; 1995; 15(3):1065-70. PubMed ID: 7645927 [TBL] [Abstract][Full Text] [Related]
8. Using molecular markers in sputum for the early detection of lung cancer: a review. Kennedy TC; Hirsch FR Lung Cancer; 2004 Aug; 45 Suppl 2():S21-7. PubMed ID: 15552778 [TBL] [Abstract][Full Text] [Related]
9. Nucleosomes and CYFRA 21-1 indicate tumor response after one cycle of chemotherapy in recurrent non-small cell lung cancer. Holdenrieder S; von Pawel J; Dankelmann E; Duell T; Faderl B; Markus A; Siakavara M; Wagner H; Feldmann K; Hoffmann H; Raith H; Nagel D; Stieber P Lung Cancer; 2009 Jan; 63(1):128-35. PubMed ID: 18571761 [TBL] [Abstract][Full Text] [Related]
10. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. Lebanony D; Benjamin H; Gilad S; Ezagouri M; Dov A; Ashkenazi K; Gefen N; Izraeli S; Rechavi G; Pass H; Nonaka D; Li J; Spector Y; Rosenfeld N; Chajut A; Cohen D; Aharonov R; Mansukhani M J Clin Oncol; 2009 Apr; 27(12):2030-7. PubMed ID: 19273703 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of the prognostic role of a panel of biomarkers in stage IB-IIIA non-small cell lung cancer patients. Timotheadou E; Skarlos DV; Samantas E; Papadopoulos S; Murray S; Skrickova J; Christodoulou C; Papakostantinou C; Pectasides D; Papakostas P; Kaplanova J; Vrettou E; Karina M; Kosmidis P; Fountzilas G Anticancer Res; 2007; 27(6C):4481-9. PubMed ID: 18214064 [TBL] [Abstract][Full Text] [Related]
12. Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas. Ishikawa N; Takano A; Yasui W; Inai K; Nishimura H; Ito H; Miyagi Y; Nakayama H; Fujita M; Hosokawa M; Tsuchiya E; Kohno N; Nakamura Y; Daigo Y Cancer Res; 2007 Dec; 67(24):11601-11. PubMed ID: 18089789 [TBL] [Abstract][Full Text] [Related]
13. Immunohystochemical expression of cancer/testis antigens (MAGE-A3/4, NY-ESO-1) in non-small cell lung cancer: the relationship with clinical-pathological features. Grah J; Samija M; Juretić A; Sarcević B; Sobat H Coll Antropol; 2008 Sep; 32(3):731-6. PubMed ID: 18982744 [TBL] [Abstract][Full Text] [Related]
14. Circulating biomarkers for lung cancer. Buccheri G Ann Ital Chir; 1999; 70(6):831-8. PubMed ID: 10804657 [TBL] [Abstract][Full Text] [Related]
15. Multiple genetic and epigenetic biomarkers for lung cancer detection in cytologically negative sputum and a nested case-control study for risk assessment. Hsu HS; Chen TP; Wen CK; Hung CH; Chen CY; Chen JT; Wang YC J Pathol; 2007 Dec; 213(4):412-9. PubMed ID: 17973238 [TBL] [Abstract][Full Text] [Related]
16. Use of tumor markers in lung cancer. Strauss GM; Skarin AT Hematol Oncol Clin North Am; 1994 Jun; 8(3):507-32. PubMed ID: 8707770 [TBL] [Abstract][Full Text] [Related]
17. Expression of LKB1 tumor suppressor in non-small cell lung cancer determines sensitivity to 2-deoxyglucose. Inge LJ; Coon KD; Smith MA; Bremner RM J Thorac Cardiovasc Surg; 2009 Mar; 137(3):580-6. PubMed ID: 19258070 [TBL] [Abstract][Full Text] [Related]
18. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature. Vilmar A; Sørensen JB Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893 [TBL] [Abstract][Full Text] [Related]
19. Detection of circulating cancer cells in lung cancer patients with a panel of marker genes. Liu L; Liao GQ; He P; Zhu H; Liu PH; Qu YM; Song XM; Xu QW; Gao Q; Zhang Y; Chen WF; Yin YH Biochem Biophys Res Commun; 2008 Aug; 372(4):756-60. PubMed ID: 18514066 [TBL] [Abstract][Full Text] [Related]
20. Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancer. Baron AT; Wilken JA; Haggstrom DE; Goodrich ST; Maihle NJ IDrugs; 2009 May; 12(5):302-8. PubMed ID: 19431095 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]